We are live on
!
Find out more
Alnylam Pharmaceuticals
ALNY
ALNY
421 hedge funds and large institutions have $16.5B invested in Alnylam Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 55 funds opening new positions, 131 increasing their positions, 161 reducing their positions, and 68 closing their positions.
New
Increased
Maintained
Reduced
Closed
40% more call options, than puts
Call options by funds: $486M | Put options by funds: $346M
0.93% less ownership
Funds ownership: 94.83% → 93.9% (-0.93%)
5% less funds holding
Funds holding: 443 → 421 (-22)
11% less capital invested
Capital invested by funds: $18.6B → $16.5B (-$2.08B)
19% less repeat investments, than reductions
Existing positions increased: 131 | Existing positions reduced: 161
19% less first-time investments, than exits
New positions opened: 55 | Existing positions closed: 68
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
Holders
421
Holders Change
-22
Holders Change %
-4.97%
% of All Funds
7.09%
Holding in Top 10
6
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-25%
% of All Funds
0.1%
New
55
Increased
131
Reduced
161
Closed
68
Calls
$486M
Puts
$346M
Net Calls
+$139M
Net Calls Change
+$195M
Top Buyers
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$244M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$173M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$113M |
| 4 |
Holocene Advisors
New York
|
-$113M |
| 5 |
JP Morgan Chase
New York
|
-$90.1M |
